- Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obesity
- Camurus Raises Full Year 2020 Revenue Guidance
- Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US
- Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid Dependence
Camurus AB (CAMX:STO) closed at 160.20, -8.46% below its 52-week high of 175.00, set on Jul 21, 2020.
61.50Mar 23 2020175.00Jul 21 2020
Markit short selling activity
|Market cap||8.59bn SEK|
|EPS (TTM)||-4.29 |
Data delayed at least 15 minutes, as of Aug 07 2020 17:00 BST.